Anebulo Pharmaceuticals Inc (ANEB)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Revenue 0 0 0 0
Cost of Revenue 0 0 0 0
Gross Profit 0 0 0 0
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 1,254,000 1,368,000 1,097,000 872,661
Operating Expenses 1,892,000 2,588,000 2,412,000 1,340,000
Operating Income -1,892,000 -2,588,000 -2,412,000 -1,340,000
Interest Expense 245,182 59,696 59,697 59,696
Income Before Tax -1,676,000 -2,463,000 -2,201,000 -1,350,000
Income Tax Expense 0 0 0 0
Net Income -1,676,000 -2,463,000 -2,201,000 -1,350,000
Per Share
EPS -0.04 -0.09 -0.08 -0.05
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Revenue 0 0 0 0 0
Cost of Revenue 0 0 0 0 0
Gross Profit 0 0 0 0 0
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 4,923,540 4,760,000 6,183,000 3,869,636 1,343,755
Operating Expenses 9,223,481 8,309,000 11,784,000 6,831,174 3,613,753
Operating Income -9,223,481 -8,309,000 -11,784,000 -6,831,174 -3,613,753
Interest Expense 382,014 151,230 0 7,332 11,767
Income Before Tax -8,484,763 -8,202,000 -11,732,000 -6,825,619 -30,252,554
Income Tax Expense 0 0 -104,000 -12,887 0
Net Income -8,484,763 -8,202,000 -11,732,000 -6,812,732 -30,252,554
Per Share
EPS -0.25 -0.32 -0.47 -0.29 -2.83
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Assets
Cash and Cash Equivalents 11,627,849 3,094,200 11,247,403 14,548,471
Short Term Investments 0 0 0 0
Net Receivables 0 0 0 0
Inventory 0 0 0 0
Total Current Assets 11,962,506 3,507,990 11,247,403 14,548,471
Property Plant Equipment 0 0 0 0
Goodwill and Intangibles 0 0 0 0
Total Assets 12,145,616 4,073,114 11,670,151 15,579,431
Liabilities
Account Payables 224,175 156,426 534,545 380,828
Short Term Debt 0 0 0 0
Total Current Liabilities 224,175 260,583 534,545 512,531
Long Term Debt 0 0 0 0
Total Liabilities 487,688 260,583 1,068,801 512,531
Shareholders Equity
Retained Earnings -73,888,507 -65,403,744 -57,202,041 -45,469,703
Total Shareholders Equity 11,657,928 3,812,531 10,601,350 15,066,900
Balance Sheet (Annual) 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Assets
Cash and Cash Equivalents 11,627,849 3,094,200 11,247,403 14,548,471 19,985,645
Short Term Investments 0 0 0 0 0
Net Receivables 0 0 0 0 0
Inventory 0 0 0 0 0
Total Current Assets 11,962,506 3,507,990 11,247,403 14,548,471 21,653,491
Property Plant Equipment 0 0 0 0 0
Goodwill and Intangibles 0 0 0 0 0
Total Assets 12,145,616 4,073,114 11,670,151 15,579,431 21,653,491
Liabilities
Account Payables 224,175 156,426 534,545 380,828 110,048
Short Term Debt 0 0 0 0 0
Total Current Liabilities 224,175 260,583 534,545 512,531 241,633
Long Term Debt 0 0 0 0 0
Total Liabilities 487,688 260,583 1,068,801 512,531 241,633
Shareholders Equity
Retained Earnings -73,888,507 -65,403,744 -57,202,041 -45,469,703 -38,644,084
Total Shareholders Equity 11,657,928 3,812,531 10,601,350 15,066,900 21,411,858
Cash Flow Statement (Quarterly) 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Activities
Net Income -8,484,763 -8,201,703 -11,732,338 -6,825,619
Depreciation & Amortization 382,014 0 0 0
Stock Based Compensation 1,446,824 758,884 884,723 480,661
Change in Working Capital 0 -799,260 1,164,482 907,784
Operating Cash Flow -6,349,687 -8,090,849 -9,683,133 -5,437,174
Investing Activities
Capital Expenditure 0 0 0 0
Investments 0 0 0 0
Investing Cash Flow 0 0 0 0
Financing Activities
Debt Repayment 0 0 0 0
Common Stock Issued/Repurchased 15,000,000 654,000 6,646,748 0
Dividends Paid 0 0 0 0
Financing Cash Flow 14,883,336 -62,354 6,382,065 0
Summary
Free Cash Flow -6,349,687 -8,090,849 -9,683,133 -5,437,174
Net Change in Cash 8,533,649 -8,153,203 -3,301,068 -5,437,174
Cash Flow Statement (Annual) 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Operating Activities
Net Income -8,484,763 -8,201,703 -11,732,338 -6,825,619 -30,252,554
Depreciation & Amortization 382,014 0 0 0 0
Stock Based Compensation 1,446,824 758,884 884,723 480,661 199,947
Change in Working Capital 0 -799,260 1,164,482 907,784 -1,445,292
Operating Cash Flow -6,349,687 -8,090,849 -9,683,133 -5,437,174 -4,871,189
Investing Activities
Capital Expenditure 0 0 0 0 0
Investments 0 0 0 0 0
Investing Cash Flow 0 0 0 0 0
Financing Activities
Debt Repayment 0 0 0 0 -201,286
Common Stock Issued/Repurchased 15,000,000 654,000 6,646,748 0 22,854,770
Dividends Paid 0 0 0 0 0
Financing Cash Flow 14,883,336 -62,354 6,382,065 0 21,831,854
Summary
Free Cash Flow -6,349,687 -8,090,849 -9,683,133 -5,437,174 -4,871,189
Net Change in Cash 8,533,649 -8,153,203 -3,301,068 -5,437,174 16,960,665